Lutetium Lu 177 Vipivotide Tetraxetan
Brand names: Pluvicto · Active ingredient: Lutetium Lu-177 Vipivotide Tetraxetan
In short: PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. PLUVICTO is indicated for the
What is Lutetium Lu 177 Vipivotide Tetraxetan used for?
PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.
PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and
are considered appropriate to delay taxane-based chemotherapy, or
have received prior taxane-based chemotherapy.
Lutetium Lu 177 Vipivotide Tetraxetan dosage
PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure . Use waterproof gloves and effective radiation shielding when handling PLUVICTO.
Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
Select patients with metastatic prostate cancer for treatment with PLUVICTO using LOCAMETZ or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors. Additional selection criteria were used in clinical studies .
Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer
The recommended dosage of PLUVICTO in combination with ARPI is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.
Refer to the Prescribing Information for ARPI for recommended dosing information.
Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
The recommended dosage of PLUVICTO is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.
Patients receiving PLUVICTO for metastatic prostate cancer should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
Recommended dosage modifications of PLUVICTO for adverse reactions are provided in Table 1. Management of adverse reactions may require temporary dose interruption, dose reduction, or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an adverse reaction persists for > 4 weeks, consider permanent discontinuation of PLUVICTO. The dose of PLUVICTO may be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose. If a patient has further adverse reactions that would require an additional dose reduction, treatment with PLUVICTO must be discontinued.
Abbreviations: CLcr, creatinine clearance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE).
Adverse reaction | Severity | Dosage modification
Myelosuppression(Anemia, thrombocytopenia, leukopenia, or neutropenia)
| Grade 2 | Withhold PLUVICTO until improvement to Grade 1 or baseline.
Grade ≥ 3 | Withhold PLUVICTO until improvement to Grade 1 or baseline.Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade ≥ 3 myelosuppression after one dose reduction | Permanently discontinue PLUVICTO. …
How to take Lutetium Lu 177 Vipivotide Tetraxetan — instructions & advice from the label
Risk From Radiation Exposure
Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation.
Before the patient is released, inform patients about the necessary radioprotection precautions to follow to minimize radiation exposure to others.
After each administration of PLUVICTO, advise patients to:
Limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days.
Refrain from sexual activity for 7 days.
Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days .
Myelosuppression
Advise patients to contact their healthcare provider for any signs or symptoms of myelosuppression, such as tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty to stop bleeding, or frequent infections with signs, such as fever, chills, sore throat or mouth ulcers .
Renal Toxicity
Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. …
Warnings & precautions
Do not take this medicine if: None.
PLUVICTO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.
Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional good radiation safety practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home.
Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation.
Before the patient is released, inform patients about the necessary radioprotection precautions to follow to minimize radiation exposure to others .
After each administration of PLUVICTO, advise patients to:
Limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days.
Refrain from sexual activity for 7 days.
Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days.
PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia.
In the PSMAddition study, Grade 3 or 4 decreased leukocytes (7%), decreased neutrophils (4.4%), decreased hemoglobin (4.3%), and decreased platelets (1.1%) occurred in patients treated with PLUVICTO.
In the PSMAfore study, Grade 3 or 4 decreased hemoglobin (7%), decreased leukocytes (4.4%), decreased neutrophils (3.5%), and decreased platelets (2.7%) occurred in patients treated with PLUVICTO. One death occurred due to bone marrow failure during long-term follow-up in a patient who received PLUVICTO. …
Lutetium Lu 177 Vipivotide Tetraxetan side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Myelosuppression
Renal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the pooled safety population for the PSMAddition, PSMAfore and VISION studies (N = 1320), the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were decreased lymphocytes (86%), decreased hemoglobin (68%), fatigue (51%), dry mouth (46%), decreased neutrophils (35%), nausea (35%), decreased platelets (33%), decreased estimated glomerular filtration rate (28%), increased aspartate aminotransferase (25%), decreased sodium (22%), increased magnesium (22%), increased potassium (21%), decreased calcium (21%), and increased alkaline phosphatase (20%).
Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer
PSMAddition
The safety of PLUVICTO in combination with ARPI was evaluated in the PSMAddition study in patients with PSMA-positive mAPMN/S prostate cancer . Patients could have been treated with ARPI in the metastatic setting for up to 45 days prior to consent. Patients received at least one dose of either PLUVICTO 7.4 GBq (200 mCi) administered every 6 weeks in combination with ARPI (N = 564) or ARPI alone (N = 565). …
About this medicine
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177.
The chemical name is 2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxy propyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate; lutetium-177(3+). The molecular mass is 1216.06 g/mol and the molecular formula is C49H68
177LuN9O16. The chemical structure for lutetium Lu 177 vipivotide tetraxetan is shown below:
PLUVICTO Injection containing 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan at calibration time is supplied as a sterile, clear, colorless to slightly yellow solution for intravenous use containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 vipivotide tetraxetan at administration time. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 14908037-2892-4d98-a053-253ce35afb1a. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate